nct_id: NCT06252649
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-02-12'
study_start_date: '2024-07-17'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: FOLFIRI Regimen'
  - drug_name: 'Drug: Bevacizumab-awwb'
  - drug_name: 'Drug: Panitumumab'
  - drug_name: 'Drug: Sotorasib'
long_title: "Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study\
  \ of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb\
  \ for Treatment-na\xEFve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C\
  \ Mutation (CodeBreaK 301)"
last_updated: '2025-08-29'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Amgen
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 450
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C
  mutation by a locally validated assay.'
- '* Central laboratory detection of KRAS p.G12C mutation.'
- '* Measurable metastatic disease per RECIST v1.1 criteria.'
- "* Eastern Cooperative Oncology Group (ECOG) Performance Status of \u2264 1."
- '* Adequate organ function.'
- 'Exclude - Exclusion Criteria:'
- Exclude - * Active, untreated brain metastases.
- Exclude - * Leptomeningeal disease
- Exclude - * Previous treatment with a KRAS p.G12C inhibitor
- Exclude - * History of interstitial pneumonitis or pulmonary fibrosis or evidence
  of interstitial pneumonitis or pulmonary fibrosis on baseline CT scan
short_title: "Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without\
  \ Bevacizumab-awwb in Treatment-na\xEFve Participants With Metastatic Colorectal\
  \ Cancer With KRAS p.G12C Mutation"
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Amgen
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: "The aim of this study is to compare progression free survival (PFS) in treatment-na\xEF\
  ve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving\
  \ sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb."
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Arm A: Sotorasib + Panitumumab + FOLFIRI'
      arm_internal_id: 0
      arm_description: Sotorasib will be taken daily (QD) as an oral tablet. Panitumumab
        and FOLFIRI will be received every 2 weeks (Q2W) via intravenous (IV) infusion.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: FOLFIRI Regimen'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Sotorasib'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Panitumumab'
        level_internal_id: 2
        level_suspended: N
    - arm_code: 'Arm B: FOLFIRI with or Without Bevacizumab-awwb'
      arm_internal_id: 1
      arm_description: Participants will receive FOLFIRI Q2W with or without bevacizumab-awwb.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: FOLFIRI Regimen'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Bevacizumab-awwb'
        level_internal_id: 1
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          disease_status:
          - Metastatic
          oncotree_primary_diagnosis: Colorectal Adenocarcinoma
      - or:
        - genomic:
            hugo_symbol: KRAS
            variant_category: Mutation
